Recuro Health has acquired MyLegacy, a risk stratification tool and clinical decision support application that uses proprietary algorithms based on practice guidelines developed by the Cleveland Clinic Genomic Medicine Institute. This acquisition further increases the scope and capabilities of Recuro’s digital health platform, pairing automated genetic data gathering with complex care planning to save time, make care more precise and streamline the full continuum of care.

Michael Gorton, CEO and founder, Recuro Health, says, “Rich genetic and genomic risk stratification supports the Recuro integrated digital approach to disease management. By integrating these software tools, Recuro helps employers and payers ascertain complex and chronic diseases that tend to run in families like cancer, cardiovascular disease, obesity, rheumatoid arthritis, Alzheimer’s disease and depression. Access to this data supports the work of coordinators who may not have access to important genetic risk factors or genetic testing results.”